Notice of Intent to Award a Sole Source Contract Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak
Key Takeaways
- Set-aside for No Set Aside businesses
- Work to be performed in Rockville, MD
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Contract Details
- Notice ID
- OC-2026-135667
- Opportunity Type
- Special Notice
- Sub-Agency
- FOOD AND DRUG ADMINISTRATION
- Office
- FOOD AND DRUG ADMINISTRATION
- Posted Date
- Friday, July 24, 2026
- Response Deadline
- Wednesday, July 29, 2026
- PSC Code
- AN13
- Set-Aside
- No Set Aside
- Place of Performance
- Rockville, MD, 20841
- Status
- Active
Description
Procurement Type: Sole Source Simplified Acquisition Procedures (SAP) Purchase Order for Commercial Items Authority: FAR Part 6.103-1, Only One Responsible Source Subject: Notice of Intent to Award a Sole Source Contract Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak Description: The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to The University of Liverpool for the Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak, in accordance with the authority under FAR Part 6.103-1, Only One Responsible Source. This procurement is being conducted under simplified acquisition procedures in accordance with FAR Part 12 (RFO). The NAICS Code for this action is 541714 - Research and Development in Biotechnology (except Nan
Why This Opportunity Matters
HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking responses for research and development in biotechnology (except nanobiotechnology) with a set-aside for No Set Aside businesses in Rockville, MD. This set-aside designation means eligible businesses face reduced competition from larger firms.
Similar Opportunities
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
